Drug Profile
Research programme: neurodegenerative disorders therapeutics - NLS Pharmaceutics Ltd
Alternative Names: NLS-5/COP2Q; NLS-6/COP5F; NLS-7/COP SFLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator NeuroLifeSciences
- Developer NLS Pharmaceutics Ltd
- Class Antidementias; Antiparkinsonians; Quinolines; Quinoxalines; Tryptamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Huntington's disease; Lewy body disease; Parkinson's disease
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Huntington's-disease in Switzerland
- 28 Jul 2022 No recent reports of development identified for preclinical development in Lewy body disease in Switzerland
- 28 Jan 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in Switzerland